Search results for "RC666-701"

showing 10 items of 122 documents

Destination Therapy with Left Ventricular Assist Devices in Non-transplant Centres: The Time is Right

2020

For almost half a century, cardiac transplant has been the only long-term treatment for patients with end-stage heart failure. Implantable left ventricular assist devices (LVADs) have emerged as a new treatment option for advanced heart failure as destination therapy for patients either too old or not suitable for transplant. A meta-analysis presenting head-to-head comparisons of cardiac transplant versus LVAD as destination therapy (LVAD-DT) found no difference in 1-year mortality rates between LVAD-DT and cardiac transplant (OR 1.49; 95% CI [0.48–4.66]; I2=82.8%). Moreover, a recent subanalysis from the Interagency Registry for Mechanically Assisted Circulatory Support found similar outco…

Cardiac transplantlcsh:Diseases of the circulatory (Cardiovascular) systemmedicine.medical_specialtyCardiomyopathy030204 cardiovascular system & hematologyoutcomes03 medical and health sciences0302 clinical medicineInternal medicineleft ventricular assist deviceDiseases of the circulatory (Cardiovascular) systemMedicine030212 general & internal medicineMyocardial infarctionStrokeHeart Failurebusiness.industryMortality rateAtrial fibrillationmedicine.diseaseequipment and supplieslcsh:RC666-701RC666-701Heart failureCirculatory systemCardiologydestination therapyCardiology and Cardiovascular MedicinebusinessDestination therapyEuropean Cardiology Review
researchProduct

Bedside chest ultrasound to distinguish heart failure from pneumonia‐related dyspnoea in older COVID‐19 patients

2020

Abstract Aims In the older population, acute heart failure is a frequent, life‐threatening complication of COVID‐19 that requires urgent specific care. We aimed to explore the impact of point‐of‐care chest ultrasound (CUS) use in older bedridden inpatients during the COVID‐19 pandemic as a tool to distinguish between cardiogenic pulmonary oedema and isolated viral pneumonia‐related dyspnoea. Methods and results This prospective series included 16 patients aged 75 or older, hospitalized for acute dyspnoea in an acute geriatric unit of a university hospital and testing positive for a SARS‐Cov2 infection. We collected demographic characteristics, medical history, biological screening, clinical…

Chest ultrasoundmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Short CommunicationShort CommunicationsContext (language use)Heart failurePoint‐of‐care ultrasound030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineOlder patientsCOVID‐19Internal medicineDyspnoeamedicineDiseases of the circulatory (Cardiovascular) systemMedical history030212 general & internal medicineAgedbusiness.industryPneumoniamedicine.diseasePneumoniaRC666-701Heart failureCardiology and Cardiovascular MedicinebusinessComplicationESC Heart Failure
researchProduct

Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: analysis on cytokines and lipid profile

2021

Abstract Lomitapide, a drug for the treatment of homozygous familial hypercholesterolemia patients, reduced total and LDL cholesterol but no significant changes were observed on PCSK9 and Lp(a) plasma levels. Some changes of inflammatory mediators were also observed, including hsCRP, which may suggest an anti-inflammatory effect.

Drugmedicine.medical_specialtymedia_common.quotation_subjectFamilial hypercholesterolemiaPCSK9chemistry.chemical_compoundInternal medicineLomitapide Lipoprotein (a) PCSK9 Familial HypercholesterolemiaLipoprotein (a)Internal MedicinemedicineDiseases of the circulatory (Cardiovascular) systemFamilial Hypercholesterolemiaskin and connective tissue diseasesmedia_commonLdl cholesterolmedicine.diagnostic_testbusiness.industryPCSK9nutritional and metabolic diseasesPlasma levelsmedicine.diseaseLomitapideLomitapidelp(a)EndocrinologychemistryRC666-701pcsk9.lipids (amino acids peptides and proteins)sense organsCardiology and Cardiovascular MedicineLipid profilebusiness
researchProduct

Predictive value of heart failure with reduced versus preserved ejection fraction for outcome in pulmonary embolism

2020

Abstract Aims This study aimed to investigate whether the risk of short‐term mortality is different in pulmonary embolism (PE) patients who have heart failure with reduced ejection fraction (HFrEF) as compared with those with heart failure with preserved ejection fraction (HFpEF). Methods and results Predictive value of HFrEF or HFpEF for 7‐day (intrahospital) and 30‐day all‐cause mortality was determined in the cohort of 1055 out of 1201 consecutive acute PE patients from the Serbian multicentre PE registry. Patients were classified into either HFrEF or HFpEF group, according to guideline‐proposed criteria. A 7‐day (intrahospital) and 30‐day all‐cause mortality was 18.5% vs. 7.3% vs. 4.5% …

Ejection fractionmedicine.medical_specialtyHeart failure030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineOriginal Research ArticlesInternal medicineDiseases of the circulatory (Cardiovascular) systemMedicineOriginal Research Article030212 general & internal medicineMortalityRisk factorEjection fractionbusiness.industryPulmonary embolismHazard ratioAtrial fibrillationmedicine.disease3. Good healthPulmonary embolismBlood pressureRC666-701Heart failureCardiologyCardiology and Cardiovascular MedicinebusinessHeart failure with preserved ejection fractionESC Heart Failure
researchProduct

Protecting against sedentary lifestyle, left atrial enlargement and atrial fibrillation.

2022

Endurance TrainingRisk FactorsRC666-701Atrial FibrillationDiseases of the circulatory (Cardiovascular) systemHumansHeart AtriaOrgan SizeSedentary BehaviorCardiology and Cardiovascular MedicineExerciseRisk AssessmentOpen heart
researchProduct

Utility of Cardiac Magnetic Resonance to assess association between admission hyperglycemia and myocardial damage in patients with reperfused ST-segm…

2008

Abstract Aims to investigate the association between admission hyperglycemia and myocardial damage in patients with ST-segment elevation myocardial infarction (STEMI) using Cardiac Magnetic Resonance (CMR). Methods We analyzed 113 patients with STEMI treated with successful primary percutaneous coronary intervention. Admission hyperglycemia was defined as a glucose level ≥ 7.8 mmol/l. Contrast-enhanced CMR was performed between 3 and 7 days after reperfusion to evaluate left ventricular function and perfusion data after injection of gadolinium-DTPA. First-pass images (FP), providing assessment of microvascular obstruction and Late Gadolinium Enhanced images (DE), reflecting the extent of in…

Gadolinium DTPAMalemedicine.medical_specialtylcsh:Diseases of the circulatory (Cardiovascular) systemMyocardial InfarctionContrast Media030204 cardiovascular system & hematologyStatistics Nonparametric030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineGadolinium DTPARisk FactorsInternal medicineImage Interpretation Computer-Assistedmedicine[INFO.INFO-IM]Computer Science [cs]/Medical ImagingST segmentHumansRadiology Nuclear Medicine and imagingIn patientMyocardial infarctioncardiovascular diseasesAngioplasty Balloon CoronaryAngiologyMedicine(all)Chi-Square DistributionRadiological and Ultrasound Technologymedicine.diagnostic_test[ INFO.INFO-IM ] Computer Science [cs]/Medical Imagingbusiness.industryResearchMagnetic resonance imagingMiddle Agedmedicine.diseaseMagnetic Resonance Imaging3. Good healthLogistic Modelslcsh:RC666-701HyperglycemiaCardiologycardiovascular systemFemaleCardiology and Cardiovascular MedicineCardiac magnetic resonancebusiness
researchProduct

Early cardiac unloading with ImpellaCP™ in acute myocardial infarction with ventricular septal defect

2020

Abstract Despite a relative contraindication, mechanical support with Impella™ left ventricular assist device has already been described for ischaemic ventricular septal defect treatment, either as a bridge to surgery, as intraoperative mechanical haemodynamic support, or to ensure intraprocedural haemodynamic stability during device closure. We describe two cases of ventricular septal defect complicating acute myocardial infarction, where the percutaneous ImpellaCP was implanted early (differently than previously described) with the aim of preventing haemodynamic instability, while deferring surgical repair. We present a report of haemodynamic, echocardiographic, biochemical, and clinical …

Heart Septal Defects Ventricularmedicine.medical_specialtyPercutaneousAcute myocardial infarction mechanical complicationmedicine.medical_treatmentMyocardial InfarctionCase ReportLeft ventricular assist device610 Medicine & health030204 cardiovascular system & hematologyVentricular septal defectImpella11171 Cardiocentro Ticino2705 Cardiology and Cardiovascular Medicine03 medical and health sciences0302 clinical medicineInternal medicineDiseases of the circulatory (Cardiovascular) systemMedicineHumans030212 general & internal medicineMyocardial infarctioncardiovascular diseasesContraindicationImpellaSurgical repairbusiness.industryHemodynamicsAcute heart failureHeartPerioperativemedicine.diseaseRC666-701Heart failureVentricular assist deviceCardiologyHeart-Assist DevicesCardiology and Cardiovascular Medicinebusiness
researchProduct

Preliminary Short-term Results of a Population of Patients Treated with MitraClip therapy: one Center Experience

2017

<p><span>Objectives: This retrospective analysis sought to evaluate 1-month outcomes and therapy effectiveness of a population of patients treated with MitraClip therapy. We describe in this article the preliminary results of primary effictiveness endpoint.</span></p><p><span>Background: Percutaneous Mitral Repair is being developed to treat severe mitral regurgitation (MR),with increasing real-world cases of functional MR(FMR). In the EVEREST(Endovascular Valve Edge-to-Edge Repair Study)II trial,percutaneous device showed superior safety but less reduction in MR at 1year. 4-year outcomes from EVEREST II trial showed no difference in the prevalence of mod…

Heart valvesmedicine.medical_specialtyeducation.field_of_studyMitral regurgitationlcsh:Diseases of the circulatory (Cardiovascular) systemPercutaneousbusiness.industryMitraClipPopulationlcsh:Rlcsh:MedicinePercutaneous approachNyha classNew york heart associationSurgerylcsh:RC666-701MedicineFunctional mrMitraClipbusinesseducationCatheter-based therapyNYHA functional classMitral RegurgitationInternational Cardiovascular Forum Journal
researchProduct

ST segment elevations: Always a marker of acute myocardial infarction?

2013

AbstractChest pain is one of the chief presenting complaints among patients attending Emergency department. The diagnosis of acute myocardial infarction may be a challenge. Various tools such as anamnesis, blood sample (with evaluation of markers of myocardial necrosis), ultrasound techniques and coronary computed tomography could be useful. However, the interpretation of electrocardiograms of these patients may be a real concern. The earliest manifestations of myocardial ischemia typically interest T waves and ST segment. Despite the high sensitivity, ST segment deviation has however poor specificity since it may be observed in many other cardiac and non-cardiac conditions. Therefore, when…

Lung Diseasesmedicine.medical_specialtyBenign early repolarizationRD1-811Gastrointestinal DiseasesChest pain Differential diagnosis ECG Myocardial infarction ST segmentReview ArticleChest painDiagnosis DifferentialChest painElectrocardiographyCardiac Conduction System DiseaseHeart Conduction SystemInternal medicineT wavemedicineHumansST segmentDiseases of the circulatory (Cardiovascular) systemMyocardial infarctionBrugada SyndromeAnamnesisbusiness.industryECGElectrocardiography in myocardial infarctionArrhythmias CardiacEmergency departmentmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareMyocardial infarctionCardiovascular DiseasesST segmentRC666-701CardiologyDifferential diagnosisSurgerymedicine.symptombusinessCardiology and Cardiovascular MedicineIndian Heart Journal
researchProduct

Impacto Clínico e Custo-Efetividade da FFR em Comparação à Angiografia em Pacientes com Doenças Multiarteriais Submetidos à ICP

2018

Abstract Background: In multivessel disease patients with moderate stenosis, fractional flow reserve (FFR) allows the analysis of the lesions and guides treatment, and could contribute to the cost-effectiveness (CE) of non-pharmacological stents (NPS). Objectives: To evaluate CE and clinical impact of FFR-guided versus angiography-guided angioplasty (ANGIO) in multivessel patients using NPS. Methods: Multivessel disease patients were prospectively randomized to FFR or ANGIO groups during a 5 year-period and followed for < 12 months. Outcomes measures were major adverse cardiac events (MACE), restenosis and CE. Results: We studied 69 patients, 47 (68.1%) men, aged 62.0 ± 9.0 years, 34 (49.2%…

MaleAcute coronary syndromemedicine.medical_specialtylcsh:Diseases of the circulatory (Cardiovascular) systemTime Factorsmedicine.medical_treatmentCost-Benefit AnalysisKaplan-Meier EstimateFractional flow reserveCoronary AngiographyRevascularizationStatistics NonparametricCoronary RestenosisAnginaAnálise de Custo BenefícioRestenosisDoença da Artéria CoronarianaInternal medicineAngioplastymedicineHumansAngina StableProspective Studiescardiovascular diseasesAcute Coronary SyndromeAngioplasty Balloon CoronaryAngioplastia Coronária com BalãoAgedmedicine.diagnostic_testbusiness.industryReserva Fracionada do Fluxo MiocárdioMiddle Agedmedicine.diseaseFractional Flow Reserve MyocardialTreatment Outcomelcsh:RC666-701AngiographyCardiologyFemaleStentsCardiology and Cardiovascular MedicinebusinessCoronary Artery Disease/economicsMaceArquivos Brasileiros de Cardiologia
researchProduct